← FDA DRUG APPROVALS

FDA NDA · NDA019693

DECABID

Sponsor: LILLY

APPLICATION
NDA019693
TYPE
NDA
ORIGINAL APPROVAL
1989-12-29
LATEST ACTION
1989-12-29
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

DECABIDDiscontinued
INDECAINIDE HYDROCHLORIDE EQ 100MG BASE · TABLET, EXTENDED RELEASE · ORAL
DECABIDDiscontinued
INDECAINIDE HYDROCHLORIDE EQ 50MG BASE · TABLET, EXTENDED RELEASE · ORAL
DECABIDDiscontinued
INDECAINIDE HYDROCHLORIDE EQ 75MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

1989-12-29Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →